Gritstone bio and Genevant Sciences Announce Option and License Agreement
15 8월 2023 - 8:00PM
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology
company that aims to develop the world’s most potent vaccines, and
Genevant Sciences, a leading nucleic acid delivery company with
world-class platforms and a robust and expansive lipid nanoparticle
(LNP) patent portfolio, today announced an agreement pursuant to
which Gritstone bio, Inc. will have a multi-year option for a
non-exclusive license under Genevant’s LNP technology on a
pathogen-by-pathogen basis to develop and commercialize
self-amplifying RNA (samRNA) vaccines.
“Our previous collaborations with Genevant have
demonstrated the powerful potential of combining the strengths of
two technology leaders, and we are pleased to expand our
relationship with this new agreement,” said Andrew Allen, M.D.,
Ph.D., Co-founder, President and Chief Executive Officer of
Gritstone bio. “With the established complementarity between our
samRNA technology and Genevant’s LNP technology, evident in
clinical datasets in both oncology and infectious disease, we are
now even better positioned to capitalize on the emergence of RNA
vaccines and therapeutics to address a broader array of infectious
diseases.”
“The key role that LNP technology has played and
can continue to play in the emergence of important medical advances
has been a focus of Genevant scientists for over two decades,” said
Pete Lutwyche, Ph.D., President and Chief Executive Officer,
Genevant Sciences Corporation. “As leaders in the field, we are
thrilled to build upon our relationship with Gritstone to pursue
new and better approaches to combat infectious disease.”
Under the terms of the agreement, Genevant is
eligible to receive from Gritstone option maintenance and exercise
fees in the single digit millions, up to $136 million in contingent
milestone payments per product, subject to increase for
multi-pathogen products and in other specified circumstances, and
royalties ranging from the mid to high single digits on future
product sales. If Gritstone outlicenses an applicable infectious
disease program, in lieu of certain of these payments, Genevant may
be entitled to a percentage of amounts that Gritstone receives from
its sublicensee.
About Gritstone bioGritstone bio,
Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company
that aims to develop the world’s most potent vaccines. We leverage
our innovative vectors and payloads to train multiple arms of the
immune system to attack critical disease targets. Independently and
with our collaborators, we are advancing a portfolio of product
candidates to treat and prevent viral diseases and solid tumors in
pursuit of improving patient outcomes and eliminating disease.
www.gritstonebio.com.
About Genevant SciencesGenevant
Sciences is a leading nucleic acid delivery company with
world-class platforms, a robust and expansive lipid nanoparticle
(LNP) patent portfolio, and decades of experience and expertise in
nucleic acid drug delivery and development. The Company’s
scientists have pioneered LNP delivery of nucleic acids for over 20
years, and the Company’s LNP platform, which has been studied
across more than a dozen discrete product candidates and is the
delivery technology behind the first and only approved systemic
RNA-LNP product (patisiran), enables a wide array of RNA-based
applications, including vaccines, therapeutic protein production,
and gene editing. For more information, please visit
www.genevant.com.
Gritstone Forward-Looking
StatementsThis press release contains
forward-looking statements, including, but not limited to,
statements related to our clinical and regulatory development plans
for our product candidates; our expectations regarding the data to
be derived in our ongoing and planned clinical trials; the timing
of commencement of our future nonclinical studies, clinical trials
and research and development programs; our ability to discover,
develop and advance product candidates into, and successfully
complete, clinical trials; and our plans and strategy regarding
maintaining existing and entering into new collaborations and/or
partnerships. Such forward-looking statements involve substantial
risks and uncertainties that could cause Gritstone’s research and
clinical development programs, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the drug development process, including Gritstone’s programs’
clinical stage of development, the process of designing and
conducting preclinical and clinical trials, the regulatory approval
processes, the timing of regulatory filings, the challenges
associated with manufacturing drug products, Gritstone’s ability to
successfully establish, protect and defend its intellectual
property and other matters that could affect the sufficiency of
existing cash to fund operations. Gritstone undertakes no
obligation to update or revise any forward-looking statements. For
a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to the
business of the company in general, see Gritstone’s most recent
Annual Report on Form 10-K filed on March 9, 2023 and any
subsequent current and periodic reports filed with
the Securities and Exchange Commission.
Gritstone
ContactsInvestors:George E. MacDougallGritstone bio,
Inc.ir@gritstone.com
Media:Dan Budwick1AB(973)
271-6085dan@1abmedia.com
Gritstone bio (NASDAQ:GRTS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Gritstone bio (NASDAQ:GRTS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024